---
document_datetime: 2025-12-19 12:39:53
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/shingrix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: shingrix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.390665
conversion_datetime: 2025-12-28 04:16:33.938714
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Shingrix

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000290774 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission | 13/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                                         | Regulation (EC) No 1234/2008. B.II.c) Control of excipients - B.II.c.z Other variation - Accepted B.II.c) Control of excipients - B.II.c.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Extension of marketing authorisation / EMA/X/0000243671 | 2. Changes to strength, pharmaceutical form and route of administration - (d) change or addition of a new pharmaceutical form - Accepted Extension application to introduce a new pharmaceutical form (suspension for injection in pre-filled syringe).                                                                                                                                                                                                                                                                      | 16/10/2025 | 18/12/2025 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                      |
| Variation type II / EMA/VR/0000263592                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC to add \"Guillain-Barre syndrome\" to the list of adverse drug reactions with frequency \"very rare\" based on the results from study EPI-ZOSTER-032 VS US DB, listed as a category 3 study in the RMP. This is a non- interventional PASS study to evaluate the | 02/10/2025 | 18/12/2025 | SmPC and PL            | The SmPC sections 4.8 and 4.4 have been updated to reflect results of study EPI-ZOSTER-032. Guillain- Barre syndrome has been included to the list of adverse drug reactions with frequency \"very rare\" and the warning has been removed from section 4.4. The Package Leaflet is updated accordingly. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | safety of Shingrix in adults ≥ 65 years of age in the United States. The Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264399 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.5 of the SmPC in order to add information on concomitant use with other vaccines based on final results from study RSV OA=ADJ-020. This is a Phase III, open-label, randomised, controlled, multi- country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with Herpes Zoster recombinant subunit (HZ/su) vaccine in adults aged 50 years and older. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the PI. | 18/09/2025 | 18/12/2025 | SmPC, Labelling and PL | Following the submission of the final study results of study RSV OA=ADJ-020, the section 4.5 of the SmPC of Arexvy and Shingrix has been updated to indicate that both vaccines can be co-administered. The primary objectives were met as non-inferiority was demonstrated for the HZ/su response, as well as for RSV-A and RSV-B. It should be noted that the geometric mean concentrations (GMCs) for anti- gE titers were numerically higher in the control group with sequential administration (61193 %CI: 55306 - 67706) compared to the Co-Ad group with concomitant administration (49327, 95%CI: 44949 - 54132), leading to a GMC ratio of 1.24 (95% CI: 1.08 - 1.42). However, the reverse cumulative distribution curves showed a similar pattern for both groups and the vaccine response rate was comparable, with VRR being 93% (95%CI 88 - 96) in the Co-Ad group and 97% (95% CI: 93-99) in the Control group. Due to the absence of a correlate for protection for anti-gE titers, it is not clear whether the observed difference in anti-gE titers will have a clinically relevant impact. It is considered that the slightly reduced response against HZ/su as observed in the Co-Ad group should not prevent the two vaccines from being given together, also taking into consideration the robust immune response still generated. It is noted that similar immunogenicity |

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                           |            |     | trends were observed in previous submissions upon concomitant administration of Arexvy with seasonal influenza vaccines, where numerically lower RSV A and B neutralising titres and numerically lower influenza A and B haemagglutination inhibition titres were observed as compared to the separate administration. This was not observed consistently across studies. Similarly, when Shingrix is co- administered with the dTpa vaccine, lower (GMCs) for one of the pertussis antigens (pertactin) was observed. The clinical relevance of this immunogenicity findings is unknown. Co administration of Arexvy and Shingrix was not associated with a clinically relevant increased risk of ADRs compared to when the vaccines were administered separately, and the safety profile of Arexvy and Shingrix co administered is comparable to the known safety profile of these two vaccines administered alone. The statements in 4.5 for co- administration of Arexvy and Shingrix with other vaccines were revised to ensure that only relevant information for prescribers is retained in the SmPC. For more information, please refer to the Summary   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000287362 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a | 05/08/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                       | starting material/intermediate - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                                                                                                                                                                                                                |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000280705 | B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.z To reflect compliance with the Ph.Eur. and remove reference to the internal test method and test method number for active substances, excipients, active substance starting materials and immediate packaging materials - Accepted                                                                                                                                                                                                                                                                                                                                                                                              | 31/07/2025 | N/A        |      |                                                                                                                                                                                                                |
| Variation type II / EMA/VR/0000267360 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC to include the final results of study ZOSTER-073, listed as a category 3 study in the RMP. This is a phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK's HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of revaccination with 2 additional doses of HZ/su vaccine, administered 1-2 months apart, 6-8 years after primary vaccination of adults with renal transplant from study | 10/07/2025 | 18/12/2025 | SmPC | The SmPC section 5.1 has been updated to include the final results of study ZOSTER-073, listed as a category 3 study in the RMP. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | been included.                                                                                                                                                                                                                                                                                                                                              |            |            |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|
| Variation type IB / EMA/VR/0000281881 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.z Other variation - Accepted                                                                                                                                                                                                                             | 08/07/2025 | N/A        |                   |
| Variation type IB / EMA/VR/0000274918 | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted | 07/07/2025 | N/A        |                   |
| Variation type IB / EMA/VR/0000269731 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                 | 17/06/2025 | 18/12/2025 | SmPC              |
| Variation type II / EMA/VR/0000235389 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or                                                                                                                                                                          | 05/06/2025 | 18/12/2025 | SmPC and Annex II |

<div style=\"page-break-after: always\"></div>

|                                       | pharmacovigilance data - Accepted Update of sections 4.4 and 5.1 of the SmPC to include the final results of study ZOSTER- 062, listed as a category 3 study in the RMP. This is a phase III, randomized, observer- blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of Shingrix when administered intramuscularly on a 0 and 2 month schedule to adults ≥ 50 years of age with a prior episode of Herpes Zoster. The RMP version 9.1 has also been approved. In addition, the MAH took the opportunity to implement a minor editorial change to Annex   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000232276 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.2 Change in test procedure for an excipient - B.II.c.2.c Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent - Accepted                                                                                                                                                                                                                                                                                    | 13/02/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000237484   | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by   | 30/01/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|